Search

Search Results

1. Procollagen C-proteinase enhancer-1 and renal failure in multiple myeloma

   Background

   Renal involvement is present in approximately 50% of multiple myeloma (MM) cases and is associated with a poor prognosis. Procollagen...

   Nergiz Bayrakci, Gülsüm Özkan, ... Aliye Çelikkol in International Urology and Nephrology

   Article 29 September 2022

2. Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis

   The outcomes of patients with myeloma after exposed to penta-classes are extremely poor. Selinexor is the first approved exportin inhibitor for those...

   Jun Ho Yi, Sung-Soo Park, ... Kihyun Kim in Annals of Hematology

   Article 25 January 2024
   

3. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma

   Multiple myeloma (MM) bears heterogeneous cells that poses a challenge for single-target immunotherapies. Here we constructed bispecific CS1-BCMA...

   Chenggong Li, Jia Xu, ... Heng Mei in Leukemia

   Article Open access 17 October 2023
   

4. The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma

   Autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for eligible patients with multiple myeloma (MM) to prolong...

   Kiarash Salafian, Christine Mazimba, ... Karen Ballen in Bone Marrow Transplantation

   Article Open access 18 January 2024
   

5. The unknown impact of multiple myeloma: assessing the impact of financial well-being on quality of life of caregivers

   Purpose

   Patients with multiple myeloma and their caregivers are financially burdened, and their quality of life is significantly affected by treatment...

   Tuba Metin, Özlem Uğur, ... Cenk Sunu in Supportive Care in Cancer

   Article 20 April 2023

6. Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients

   Trace elements are essential micronutrients for the human body. Their roles are indispensable, as they are involved in a wide range of vital...

   Ayse Nilgun Kul, Bahar Ozturk Kurt in Clinical and Experimental Medicine

   Article Open access 17 April 2024

7. Thrombosis events in Chinese patients with newly diagnosed multiple myeloma

   A high risk of thrombosis is seen in patients with newly diagnosed multiple myeloma (NDMM), particularly those treated with immunomodulatory drugs...

   Panpan Li, Bei Xu, ... Peng Liu in Clinical and Experimental Medicine

   Article 27 April 2023
   

8. Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

   This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015–2019, to characterize adult patients newly...

   Jarno Ruotsalainen, Leena Lehmus, ... Maarit Jaana Korhonen in Annals of Hematology

   Article Open access 12 December 2023
   

9. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy

   Immune dysregulation is a hallmark of clinically active multiple myeloma (MM). Interactions between malignant clonal cells and immune cells within...

   Brian M. Russell, David E. Avigan in International Journal of Hematology

   Article 25 March 2023
   

10. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)

    Prognostic significance of multiple immune antigens in multiple myeloma has been well established. However, a level of uncertainty remains regarding...

    Lihui Shi, Wenqiang Yan, ... Gang An in Annals of Hematology

    Article 05 December 2023
    

11. Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study

    Background

    Autologous hematopoietic stem cell transplant plays an important role in multiple myeloma (MM) treatment. Increasing incidence of MM and...

    Natacha Rodrigues, Claudia Costa, ... José António Lopes in Journal of Nephrology

    Article Open access 29 November 2023
    

12. Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation

    Background

    F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is useful in multiple myeloma (MM) for initial workup...

    Hyunjong Lee, Seung Hyup Hyun, ... Kyung-Han Lee in Cancer Imaging

    Article Open access 27 October 2023
    

13. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

    B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple...

    Jieyun **a, Zhenyu Li, Kailin Xu in Journal of Hematology & Oncology

    Article Open access 05 June 2023

14. Lumbar MR-based radiomics nomogram for detecting minimal residual disease in patients with multiple myeloma

    Objectives

    Minimal residual disease (MRD) is a standard for assessing treatment response in multiple myeloma (MM). MRD negativity is considered to be...

    Zengjie Wu, Hexiang Wang, ... Tiantian Bian in European Radiology

    Article 28 March 2023
    

15. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

    Background

    Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma...

    **n Miao, Liviawati S. Wu, ... Suzette Girgis in Targeted Oncology

    Article Open access 15 September 2023
    

16. Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse

    Introduction

    mSMART classifies high-risk Multiple Myeloma patients into Double Hit and Triple Hit Myeloma (DH/THM) on the basis of the number of...

    Charanpreet Singh, Vandana Panakkal, ... Pankaj Malhotra in Indian Journal of Hematology and Blood Transfusion

    Article 28 September 2022

17. Novel methyltransferase G9a inhibitor induces ferroptosis in multiple myeloma through Nrf2/HO-1 pathway

    Multiple myeloma (MM) is a common malignant hematologic neoplasm, and the involvement of epigenetic modifications in its development and drug...

    Yu Zhang, **aoshun Wang, ... Lijuan Wang in Annals of Hematology

    Article 27 March 2024
    

18. Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

    Patients with multiple myeloma (MM) are at high risk for infections, including opportunistic infections such as Pneumocystis jirovecii pneumonia...

    C Riedhammer, J Düll, ... L Rasche in Annals of Hematology

    Article Open access 20 December 2023

19. A gene signature can predict risk of MGUS progressing to multiple myeloma

    Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients...

    Fumou Sun, Yan Cheng, ... Fenghuang Zhan in Journal of Hematology & Oncology

    Article Open access 29 June 2023
    

20. Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma

    Background and Objective

    We aimed to quantify the daratumumab concentration- and CD38 dynamics-dependent pharmacokinetics using a pharmacodynamic...

    **a Li, Anne-Gaëlle Dosne, ... Juan Jose Perez Ruixo in Clinical Pharmacokinetics

    Article 06 April 2023